Treatment with bendamustine prior to CAR T-cell therapy in patients with refractory large B-cell lymphoma associates with poorer treatment outcomes, finds a recent study. Led by investigators of the ...

The 2-drug regimen was "much better tolerated" and, to the surprise of the investigators, the efficacy was not only noninferior, it showed "a clear and statistically significant superiority," said ...

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard of care for patients with multiple myeloma (MM). PBSC engraftment occurs more rapidly with infusion of ⩾5 × ...

The bendamustine molecule is composed of 3 structural elements: a mechlorethamine (nitrogen mustard) group, a benzimidazole ring, and a butyric acid side chain (Figure 1). The mechlorethamine ...

Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group A total of 245 courses (median, four ...

A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...

A review published in Transfusion Medicine Reviews discussed the 2 therapeutic approaches and their pros and cons for treating cold agglutinin disease (CAD). CAD is a rare hemolytic disorder that ...

Bendamustine treatment before apheresis is known to reduce survival in large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T-cell therapy. Bendamustine has been shown to ...

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial The study included CAR T-cell ...

The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG), and the technical report developed through engagement with stakeholders.

“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an ...